STC's cryosurgical system's expanded uses:
This article was originally published in Clinica
STC Technologies has received 510(k) clearance from the US FDA to market its Histofreezer portable cryosurgical system for treating actinic keratosis and lentigo (liver spots). Acitinic keratosis is often a precursor to skin cancer and if treated early, remains harmless, according to the Lehigh Valley, Pennsylvania-based company. The device consists of a canister of cryogen which is applied to the lesions through an attached foam bud and is also used for the treatment of other skin abnormalities such as common warts and genital lesions.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.